Secondary hyperparathyroidism (SHPT), a common complication of end-stage renal disease (ESRD), results from abnormal changes affecting calcium homeostasis and presents with the increased secretion of parathyroid hormone (PTH) [1]. This evidence concerns the gene PTH and stage 5 chronic kidney disease.